Tyra Biosciences (TYRA) Stock Price, News & Analysis

Company Overview

Tyra Biosciences is a clinical-stage biotechnology company headquartered in South San Francisco, California, that focuses on the discovery and development of precision oncology therapies. Founded in 2019, the company leverages a structure-based drug design platform to identify and optimize small-molecule inhibitors that target cancer-driving proteins. Tyra Biosciences has built a pipeline of novel compounds designed to address genetically defined patient populations with high unmet medical need.

The company’s core activities span target discovery, medicinal chemistry, and preclinical development. Utilizing computational modeling and biophysical screening techniques, Tyra Biosciences aims to create molecules with high selectivity and favorable pharmacokinetic properties. Its preclinical portfolio includes candidates designed to inhibit mutant kinases and modulate protein homeostasis pathways, with the goal of advancing lead compounds into Investigational New Drug (IND) applications.

Tyra Biosciences serves a global oncology community through strategic collaborations with academic research institutions and contract research organizations. The company’s research programs benefit from partnerships that provide access to translational biology expertise, patient-derived models, and biomarkers to guide clinical strategy. Although primarily based in the United States, Tyra Biosciences maintains engagement with international investigators to support multi-regional studies.

Under the leadership of Chief Executive Officer Dr. Elan Holman and a management team with extensive experience in cancer drug development, Tyra Biosciences is committed to advancing targeted therapies from the laboratory to the clinic. The company’s scientific advisory board comprises seasoned oncology researchers who contribute to program prioritization and clinical design, positioning Tyra Biosciences to address critical gaps in precision medicine.

Key Stats

• Today's Range: $9.98 to $10.49
• 50-Day Range: $8.82 to $10.86
• 52-Week Range: $6.42 to $29.60
• Volume: 267,847 shs
• Average Volume: 287,568 shs
• Market Capitalization: $542.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.83
• Consensus Rating: Buy

Tyra Biosciences Stock Analysis - MarketRank™

Tyra Biosciences scored higher than 35% of companies evaluated by MarketBeat, and ranked 704th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tyra Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.57) to ($2.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tyra Biosciences is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tyra Biosciences is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tyra Biosciences has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.41% of the float of Tyra Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Tyra Biosciences has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.

Change versus previous month

Short interest in Tyra Biosciences has recently increased by 5.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tyra Biosciences does not currently pay a dividend.

Dividend Growth

Tyra Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.41% of the float of Tyra Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Tyra Biosciences has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.

Change versus previous month

Short interest in Tyra Biosciences has recently increased by 5.62%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.19

News Sentiment

Tyra Biosciences has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Tyra Biosciences this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for TYRA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $628,358.00 in company stock.

Percentage Held by Insiders

15.20% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TYRA Stock Analysis - Frequently Asked Questions

How have TYRA shares performed this year?

Tyra Biosciences' stock was trading at $13.90 on January 1st, 2025. Since then, TYRA shares have decreased by 26.5% and is now trading at $10.21.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02.

When did Tyra Biosciences IPO?

Tyra Biosciences (TYRA) raised $100 million in an IPO on Wednesday, September 15th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tyra Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tyra Biosciences investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TYRA
• CIK: 1863127
• Web: www.tyra.bio
• Phone: 619-728-4760
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tyra Biosciences: $30.83
• High Price Target: $33.00
• Low Price Target: $28.00
• Potential Upside/Downside: +211.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.90%
• Return on Assets: -25.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.78
• Quick Ratio: 22.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.78 per share
• Price / Book: 1.46

Miscellaneous

• Outstanding Shares: 53,090,000
• Free Float: 45,020,000
• Market Cap: $526.12 million
• Optionable: Optionable
• Beta: 1.07